Stock 2171 CARSGEN THERAPEUTICS HOLDINGS LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

News CARsgen Therapeutics Holdings Limited

Equities

2171

KYG1996C1006

Delayed Hong Kong S.E.
Other stock markets
 04:08:20 2024-05-14 EDT 		5-day change 1st Jan Change
6.16 HKD +1.65% Intraday chart for CARsgen Therapeutics Holdings Limited +4.76% -5.23%
04-30 CARsgen Therapeutics Holdings Limited Announces Abstracts from the Ongoing Studies of zevorcabtagene autoleucel and CT071 to be Presented as an Oral Presentation and a Poster Presentation, Respectively, at the Upcoming EHA 2024 CI
04-29 CARsgen Therapeutics Holdings Limited Announces Board and Committee Changes CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
CARsgen Submitted Responses to FDA Observations
AQ
CARsgen Therapeutics Holdings Limited Announces Abstracts from the Ongoing Studies of zevorcabtagene autoleucel and CT071 to be Presented as an Oral Presentation and a Poster Presentation, Respectively, at the Upcoming EHA 2024
CI
CARsgen Therapeutics Holdings Limited Announces Board and Committee Changes
CI
CARsgen Therapeutics Holdings Limited Submits Responses to FDA Observations
CI
Carsgen Therapeutics To Give Cancer Drug Oral Presentation at ASCO 2024
MT
CARsgen Therapeutics Holdings Limited Reports Earnings Results for the Full Year Ended December 31, 2023
CI
NMPA Approves the NDA for CARsgen's BCMA CAR-T Therapy Zevorcabtagene Autoleucel for Relapsed or Refractory Multiple Myeloma
AQ
CARsgen Therapeutics’ New Drug Application for Multiple Myeloma Drug Gets Approval from Chinese Regulator
MT
National Medical Products Administration of China Approves New Drug Application of CARsgen Therapeutics Holdings Limited for Zevorcabtagene Autoleucel
CI
CARsgen Presents Data from Phase 1B Study on Gastric, Gastroesophageal Junction Cancer Drug at US Meet
MT
Carsgen Therapeutics Holdings Limited Announces Updated Clinical Research Results on CT041 at 2024 ASCO GI Meeting
CI
CARsgen's CT011 achieves IND clearance from the NMPA for the GPC3-positive stage a hepatocellular carcinoma at high risk of recurrence after surgical resection
AQ
China Grants CARsgen Clinical Trial Clearance for Liver Cancer Treatment; Shares Rise 3%
MT
CARsgen Therapeutics Holdings Limited Announces CT011 Achieve Investigational New Drug Clearance from the National Medical Products Administration
CI
CARsgen Therapeutics Holdings Shareholder Plans Stake Boost; Shares Fall 6%
MT
US FDA Puts CARsgen's Three Drug Candidates Under Clinical Hold Following Factory Inspections; Shares Plummet 27%
MT
CARsgen Therapeutics Presents Anti-Cancer Drug Data at American Conference
MT
CARsgen Therapeutics Holdings Presents Results of Study for Myeloma Treatment
MT
CARsgen Therapeutics Holdings Limited Announces Updated Research Results on Zevor-cel At 2023 American Society of Hematology Annual Meeting
CI
CARsgen's CT071 Received IND Clearance from the FDA for Treating Relapsed, Refractory Multiple Myeloma or Relapsed, Refractory Primary Plasma Cell Leukemia
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 2171 Stock
  4. News CARsgen Therapeutics Holdings Limited
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW